Do I need a prescription for Tranylcypromine 10mg tablets?

Tranylcypromine 10mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Tranylcypromine 10mg tablets?

Tranylcypromine 10mg tablets is the generic name. It is available under brand names including: Tranylcypromine 10mg tablets, Tranylcypromine 10mg tablets, Tranylcypromine 10mg tablets, Tranylcypromine 10mg tablets, Tranylcypromine 10mg tablets and 9 more. (Source: NHS dm+d — Actual Medicinal Products)

Tranylcypromine 10mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

10mg

Oral

A propylamine formed from the cyclization of the side chain of amphetamine.

Active ingredients:

Tranylcypromine

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N06AF04

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Tranylcypromine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Tranylcypromine

Source: MHRA Products DatabaseOGL 3.0

Updated 16 Jan 2026

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Tranylcypromine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Tranylcypromine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

14 branded products available

14 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Tranylcypromine on the MHRA register

Tranylcypromine 10mg tablets

A A H Pharmaceuticals Ltd

Tranylcypromine 10mg tablets

Advanz Pharma

Tranylcypromine 10mg tablets

Alliance Healthcare (Distribution) Ltd

Tranylcypromine 10mg tablets

CST Pharma Ltd

Tranylcypromine 10mg tablets

Medihealth (Northern) Ltd

Tranylcypromine 10mg tablets

Rivopharm (UK) Ltd

Tranylcypromine 10mg tablets

Glenmark Pharmaceuticals Europe Ltd

Tranylcypromine 10mg tablets

Necessity Supplies Ltd

Tranylcypromine 10mg tablets

Aristo Pharma Ltd

Tranylcypromine 10mg tablets

Accord-UK Ltd

Tranylcypromine 10mg tablets

Waymade Healthcare Plc

Discontinued

Tranylcypromine 10mg tablets

DE Pharmaceuticals

Discontinued

Source: NHS dm+dOGL 3.0

Updated 1 Mar 2026

Price & daily dose

£485.00indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

10 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

4 similar

Tablets & capsules

(3)

Phenelzine 15mg capsules

Capsule

15mg

Same therapeutic group

Isocarboxazid 10mg tablets

Tablet

10mg

Same therapeutic group

Phenelzine 15mg tablets

Tablet

15mg

Same therapeutic group

Oral liquids

(1)

Isocarboxazid 20mg/5ml oral suspension

Oral suspension

20mg/5ml

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

39708811000001101

dm+d ID

39708811000001101

VTM (Virtual Therapeutic Moiety)

777822008

VMP (Virtual Medicinal Product)

39708811000001101

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N06AF04

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 18 · 1963–2025

Sort

Efficacy and Adverse Effects of Tranylcypromine and Tricyclic Antidepressants in the Treatment of Depression

S. Ulrich, Roland Ricken, Pichit Buspavanich, et al.

Journal of Clinical Psychopharmacology, 2019

Meta-analysis

Highly cited for its field

Cited by 191

Affect
Antidepressive Agents, Tricyclic
Depression

Tranylcypromine in mind (Part I): Review of pharmacology

S. Ulrich, Roland Ricken, Mazda Adli

European Neuropsychopharmacology, 2017

Review

Highly cited for its field

Cited by 237

Depressive Disorder
Drug Interactions
Monoamine Oxidase Inhibitors

Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression

Roland Ricken, S. Ulrich, Peter Schlattmann, et al.

European Neuropsychopharmacology, 2017

Review

Highly cited for its field

Cited by 224

Antidepressive Agents
Depression
Monoamine Oxidase

60 Years of Combining Tranylcypromine

E. Wagner, F. Seemüller, A. Hasan

Journal of Clinical Psychopharmacology, 2022

Systematic review

Cited by 29

60 Years of Combining Tranylcypromine: A Systematic Review of Available Evidence

2022

Systematic review

Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment

Yi C. Zheng, Bin Yu, Guo Z. Jiang, et al.

Current Topics in Medicinal Chemistry, 2016

Review

Highly cited for its field

Cited by 96

Antineoplastic Agents
Clinical Trials as Topic
Enzyme Inhibitors

Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.

R. Cowdry, D. Gardner

Archives of general psychiatry, 1988

Cited by 399

Tranylcypromine versus imipramine in anergic bipolar depression

Jonathan M. Himmelhoch, Michael E. Thase, Alan G. Mallinger, et al.

American Journal of Psychiatry, 1991

Cited by 360

Ambulatory Care
Bipolar Disorder
Imipramine

Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

P. McGrath, D. M., Jonathan W. Stewart, et al.

The American journal of psychiatry, 2006

Highly cited for its field

Cited by 355

Venlafaxine Hydrochloride
Mirtazapine
Antidepressive Agents

Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2

Claudia Binda, Sérgio Valente, Mauro Romanenghi, et al.

Journal of the American Chemical Society, 2010

Highly cited for its field

Cited by 285

Antineoplastic Agents
Cell Line
Drug Synergism

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

137 found

Half-life

1.5-3.2 hours

Mechanism

Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO).

Food interactions

3 warnings

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

2-3 hours

Interindividual variability in absorption. May be biphasic in some individuals.…

Half-life

1.5-3.2 hours

1.5-3.2 hours in patients with normal renal and hepatic function

Volume of distribution

1.1-5.7 L/kg

1.1-5.7 L/kg

Metabolism

Hepatic.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311).

Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).

Properties:

solid

Avg. mass: 133.19 Da

DrugBank indication

For the treatment of major depressive episode without melancholia.

Also known as(76)

(±)-trans-2-phenylcyclopropylamine

(1R*,2S*)-2-phenylcyclopropan-1-amine

dl-tranylcypromine

Racemic Tranylcypromine

Tranilcipromina

trans-2-phenylcyclopropylamine

trans-DL-2-Phenylcyclopropylamine

Transamine

Molecular properties(18)

Drug interactions(1520)

Known interactions with other medicines. Always consult a healthcare professional.

Risperidone

Moderate

DB00734

Tranylcypromine may increase the hypotensive activities of Risperidone.

Check this interaction

Cilostazol

Moderate

DB01166

The serum concentration of Cilostazol can be increased when it is combined with Tranylcypromine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.

Check this interaction

Dronabinol

Moderate

DB00470

The serum concentration of Dronabinol can be increased when it is combined with Tranylcypromine.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Tranylcypromine may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.

Check this interaction

Orphenadrine

Moderate

DB01173

Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.

Check this interaction

Pramipexole

Moderate

DB00413

Tranylcypromine may increase the sedative activities of Pramipexole.

Check this interaction

Rotigotine

Moderate

DB05271

Tranylcypromine may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Moderate

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Tranylcypromine.

Check this interaction

Sodium oxybate

Moderate

DB09072

Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Thalidomide

Moderate

DB01041

Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Yohimbine

Moderate

DB01392

The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Yohimbine.

Check this interaction

Eliglustat

Moderate

DB09039

The metabolism of Eliglustat can be decreased when combined with Tranylcypromine.

Check this interaction

Ibrutinib

Moderate

DB09053

The metabolism of Ibrutinib can be decreased when combined with Tranylcypromine.

Check this interaction

Brexpiprazole

Moderate

DB09128

The metabolism of Brexpiprazole can be decreased when combined with Tranylcypromine.

Check this interaction

Desmopressin

Moderate

DB00035

The risk or severity of hypertension can be increased when Desmopressin is combined with Tranylcypromine.

Check this interaction

Icosapent

Moderate

DB00159

The risk or severity of hypertension can be increased when Icosapent is combined with Tranylcypromine.

Check this interaction

Mesalazine

Moderate

DB00244

The risk or severity of hypertension can be increased when Mesalazine is combined with Tranylcypromine.

Check this interaction

Tolmetin

Moderate

DB00500

The risk or severity of hypertension can be increased when Tolmetin is combined with Tranylcypromine.

Check this interaction

Fenoprofen

Moderate

DB00573

The risk or severity of hypertension can be increased when Fenoprofen is combined with Tranylcypromine.

Check this interaction

Sulindac

Moderate

DB00605

The risk or severity of hypertension can be increased when Sulindac is combined with Tranylcypromine.

Check this interaction

Sulfasalazine

Moderate

DB00795

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Sulfasalazine.

Check this interaction

Carprofen

Moderate

DB00821

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Carprofen.

Check this interaction

Phenmetrazine

Moderate

DB00830

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Phenmetrazine.

Check this interaction

Diflunisal

Moderate

DB00861

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Diflunisal.

Check this interaction

Meclofenamic acid

Moderate

DB00939

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Meclofenamic acid.

Check this interaction

Oxaprozin

Moderate

DB00991

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Oxaprozin.

Check this interaction

Balsalazide

Moderate

DB01014

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Balsalazide.

Check this interaction

Ephedrine

Moderate

DB01364

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Ephedrine.

Check this interaction

Magnesium salicylate

Moderate

DB01397

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Magnesium salicylate.

Check this interaction

Salsalate

Moderate

DB01399

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Salsalate.

Check this interaction

Choline magnesium trisalicylate

Moderate

DB01401

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Choline magnesium trisalicylate.

Check this interaction

Antrafenine

Moderate

DB01419

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Antrafenine.

Check this interaction

Tiaprofenic acid

Moderate

DB01600

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tiaprofenic acid.

Check this interaction

Epicaptopril

Moderate

DB02032

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Epicaptopril.

Check this interaction

Taxifolin

Moderate

DB02224

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Taxifolin.

Check this interaction

Oxyphenbutazone

Moderate

DB03585

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Oxyphenbutazone.

Check this interaction

1-benzylimidazole

Moderate

DB04581

The risk or severity of hypertension can be increased when Tranylcypromine is combined with 1-benzylimidazole.

Check this interaction

Benoxaprofen

Moderate

DB04812

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Benoxaprofen.

Check this interaction

Metamizole

Moderate

DB04817

The risk or severity of hypertension can be increased when Tranylcypromine is combined with Metamizole.

Check this interaction

Showing 50 of 1520 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol. Ingesting alcohol may increase the CNS depressant effects of tranylcypromine.

Advice

Avoid St. John's Wort. Administering tranylcypromine with St. John's Wort may increase the risk of serotonin syndrome.

Avoid Alcohol

Avoid tyramine-containing foods and supplements. Tyramine-containing foods and beverages can cause a sudden elevation in blood pressure or a hypertensive crisis. Foods that contain tyramine include aged cheese, ripe bananas, red wine, some alcoholic beverages (beer), cured food, pickled food, and fava beans.

Toxicity & overdose

In overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms.

Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.

How it works

Mechanism of action

Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.

Pharmacodynamics

Tranylcypromine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. MAO is an enzyme that catalyzes the oxidative deamination of a number of amines, including serotonin, norepinephrine, epinephrine, and dopamine. Two isoforms of MAO, A and B, are found in the body. MAO-A is mainly found within cells located in the periphery and catalyzes the breakdown of serotonin, norepinephrine, epinephrine, dopamine and tyramine. MAO-B acts on phenylethylamine, norepinephrine, epinephrine, dopamine and tyramine, is localized extracellularly and is found predominantly in the brain. While the mechanism of MAOIs is still unclear, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. It has been postulated that depression is caused by low levels of serotonin and/or norepinephrine and that increasing serotonergic and norepinephrinergic neurotransmission results in relief of depressive symptoms. MAO A inhibition is thought to be more relevant to antidepressant activity than MAO B inhibition. Selective MAO B inhibitors, such as selegiline, have no antidepressant effects.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Interindividual variability in absorption. May be biphasic in some individuals. Peak plasma concentrations occur in one hour following oral administration with a secondary peak occurring within 2-3 hours.

Biphasic absorption may represent different rates of absorption of the stereoisomers of the drug, though additional studies are required to confirm this.

Half-life

1.5-3.2 hours in patients with normal renal and hepatic function

Volume of distribution

1.1-5.7 L/kg

Metabolism

Hepatic.

Drug targets(2)

Proteins and enzymes this drug interacts with in the body

Amine oxidase [flavin-containing] B

BE0002196

MAOB

inhibitor

Specific functionelectron transfer activity

Cellular location

Mitochondrion outer membrane

General function & pharmacology

Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues .
PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924

Preferentially degrades benzylamine and phenylethylamine PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924

Amine oxidase [flavin-containing] A

BE0002198

MAOA

inhibitor

Specific functionflavin adenine dinucleotide binding

Cellular location

Mitochondrion outer membrane

General function & pharmacology

Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues .
PMID:18391214 PMID:20493079 PMID:24169519 PMID:8316221

Preferentially oxidizes serotonin .
PMID:20493079 PMID:24169519
Also catalyzes the oxidative deamination of kynuramine to 3-(2-aminophenyl)-3-oxopropanal that can spontaneously condense to 4-hydroxyquinoline (By similarity)

Metabolizing enzymes(6)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2D6Cytochrome P450 2D6

inhibitor

CYP2C9Cytochrome P450 2C9

inhibitor

CYP2C19Cytochrome P450 2C19

inhibitor

CYP1A2Cytochrome P450 1A2

inhibitor

CYP2A6Cytochrome P450 2A6

inhibitor

CYP3A4Cytochrome P450 3A4

inhibitor

Scientific references(2)

Frieling H., Bleich S.

Tranylcypromine.

European Archives of Psychiatry and Clinical Neuroscience

2006256(5):268-273. doi: 10.1007/s00406-006-0660-8

PMID: 16927039 DOI: 10.1007/s00406-006-0660-8

Nolen W.A.

Review for "Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: an exploratory case cohort study". 2022. doi: 10.

1111/acps

13518/v1/review1

PMID: 14574774 DOI: 10.1111/acps.13518/v1/review1

ATC classification(1 code)

ATC N06AF04

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Tranylcypromine sulfate(DBSALT000960)

Experimental properties(3)

External resources(3)

RxList PDRhealth Drugs.com

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Tranylcypromine

DB00752

CAS number

155-09-9

UNII (FDA)

3E3V44J4Z9

InChI Key (molecular fingerprint)

AELCINSCMGFISI-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

5882

ChEBI

131512

PubChem Compound

5530

PubChem Substance

46505832

KEGG Compound

C07155

KEGG Drug

D08625

ChemSpider

5329

BindingDB

50113851

PharmGKB

PA451741

PDB

GJZ

Therapeutic Targets Database

DAP000081

Wikipedia

Tranylcypromine

ChEMBL

CHEMBL313833

RxCUI

10734

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6834

GenAtlas

MAOB

GeneCards

MAOB

GenBank Gene Database

S62734

GenBank Protein Database

398415

Guide to Pharmacology

2490

UniProtKB

P27338

UniProt Accession

AOFB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6833

GenAtlas

MAOA

GeneCards

MAOA

GenBank Gene Database

M68840

GenBank Protein Database

187353

Guide to Pharmacology

2489

UniProtKB

P21397

UniProt Accession

AOFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2610

GenAtlas

CYP2A6

GeneCards

CYP2A6

GenBank Gene Database

X13897

Guide to Pharmacology

1321

UniProtKB

P11509

UniProt Accession

CP2A6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite:

DrugBank 6.02024Recommended citation
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
PMID: 37953279
DrugBank 5.02018
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
PMID: 29126136
DrugBank 4.02014
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
PMID: 24203711
DrugBank 3.02011
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
PMID: 21059682
DrugBank 2.02008
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
PMID: 18048412
DrugBank 1.02006
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 8 Mar 2026

Back to medicines

Tranylcypromine 10mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

Tablets & capsules

Oral liquids

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Volume of distribution

Metabolism

Clinical essentials

Pharmacology

Deep science
8

Chemical identifiers

Tranylcypromine

Additional database identifiers

DrugBank citations

Tranylcypromine 10mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Tablets & capsules

Oral liquids

Prescribing statistics

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Volume of distribution

Metabolism

Clinical essentials

Pharmacology

Deep science8

Chemical identifiers

Tranylcypromine

Additional database identifiers

DrugBank citations

Deep science
8